BRD4/CK2-IN-1
CAT:
804-HY-145260-03
Size:
25 mg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No
BRD4/CK2-IN-1
- CAS Number: 2756851-99-5
- UNSPSC Description: BRD4/CK2-IN-1 is the first highly effective and oral active dual-target inhibitor of BRD4/CK2 (bromodomain-containing protein 4/casein kinase 2), with IC50s of 180 nM and 230 nM for BRD4 and CK2, respectively. BRD4/CK2-IN-1 has strong anticancer activity without obvious toxicities. BRD4/CK2-IN-1 induces apoptosis and autophagy-associated cell death in triple-negative breast cancer (TNBC)[1]
- Target Antigen: Apoptosis; Autophagy; Casein Kinase; Epigenetic Reader Domain
- Type: Reference compound
- Related Pathways: Apoptosis;Autophagy;Cell Cycle/DNA Damage;Epigenetics;Stem Cell/Wnt
- Applications: Cancer-Kinase/protease
- Field of Research: Cancer
- Assay Protocol: https://www.medchemexpress.com/brd4-ck2-in-1.html
- Solubility: DMSO : 20 mg/mL (ultrasonic;warming;adjust pH to 3 with HCl;heat to 60°C)
- Smiles: O=C1C2=C(OC)C=C(OC)C=C2N=C(C3=CC=C(OCC(NC4=CC(Cl)=C(N5CCN(C)CC5)C=C4)=O)C=C3)N1
- Molecular Weight: 564.03
- References & Citations: [1] Zhang J, et al. Discovery of Novel Dual-Target Inhibitor of Bromodomain-Containing Protein 4/Casein Kinase 2 Inducing Apoptosis and Autophagy-Associated Cell Death for Triple-Negative Breast Cancer Therapy. J Med Chem. 2021;64(24):18025-18053.
- Shipping Conditions: Room Temperature
- Clinical Information: No Development Reported